<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Current approaches to block KRAS oncogene function focus on inhibition of K-Ras downstream effector signaling </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the antitumor activity of selumetinib (AZD6244, ARRY-142886), a potent and selective MEK1/2 inhibitor, on a panel of colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) cells and found no inhibition of KRAS mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell anchorage-independent growth </plain></SENT>
<SENT sid="2" pm="."><plain>Although AKT activity was elevated in KRAS mutant cells, and PI3K inhibition did impair the growth of MEK inhibitor-insensitive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines, concurrent treatment with selumetinib did not provide additional antitumor activity </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, we speculated that inhibition of the Ral <z:chebi fb="1" ids="16235">guanine</z:chebi> exchange factor (RalGEF) effector pathway may be a more effective approach for blocking <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> growth </plain></SENT>
<SENT sid="4" pm="."><plain>RalGEFs are activators of the related RalA and RalB small GTPases and we found activation of both in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines and patient <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Interfering <z:chebi fb="40" ids="33697">RNA</z:chebi> stable suppression of RalA expression reduced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell anchorage-independent growth, but surprisingly, stable suppression of RalB greatly enhanced soft agar colony size and formation frequency </plain></SENT>
<SENT sid="6" pm="."><plain>Despite their opposing activities, both RalA and RalB regulation of anchorage-independent growth required interaction with RalBP1/RLIP76 and components of the exocyst complex </plain></SENT>
<SENT sid="7" pm="."><plain>Interestingly, RalA interaction with the Exo84 but not Sec5 exocyst component was necessary for supporting anchorage-independent growth, whereas RalB interaction with Sec5 but not Exo84 was necessary for inhibition of anchorage-independent growth </plain></SENT>
<SENT sid="8" pm="."><plain>We suggest that anti-RalA-selective therapies may provide an effective approach for KRAS mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>